Economic evaluation of hematopoietic stem cell transplantation

References

• Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1987.
   Google Scholar
• Barr R, Furlong W, Henwood J, Feeny D, Wegener J, Walker I, et al.. Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol. 1996;14:1413–20.
   PubMed Web of Science ®Google Scholar
• Stranges E, Russo CA, Friedman B. Procedures with the most rapidly increasing hospital costs, 2004–2007. HCUP statistical brief #82. December 2009. Agency for Healthcare Research and Quality, Rockville, MD, USA. http://www.hcup-us.ahrq-gov/reports/statbriefs/sb82.pdf
   Google Scholar
• Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, et al.. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukemia: a systematic review. Health Technol Assess. 2010;14(54) :iii–iv, ix–xi, 1–141.
   Google Scholar
• Lin Y-F, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, et al.. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010;16:1272–81.
   PubMed Web of Science ®Google Scholar
• Madero L, Gonzalez VM, Ramirez M, Quintero V, Benito A, Diaz MA. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant. 2000;26:269–73.
   PubMed Web of Science ®Google Scholar
• Vellenga E, Agthoven M, Croockewit LF, Verdonck LF, Wijermans PJ, van Oers MH, et al.. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol. 2001;114:319–26.
   PubMed Web of Science ®Google Scholar
• Howard DH, Meltzer D, Kollman C, Maiers M, Logan B, Gragert L, et al.. Use of cost effectiveness analysis to determine inventory size for national cord blood bank. Med Decis Making. 2008;28:243–53.
   PubMed Web of Science ®Google Scholar
• Van Agthoven M, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, et al.. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukemia or acute lymphoblastic leukemia. Bone Marrow Transplant. 2002;30:243–51.
   PubMed Web of Science ®Google Scholar
• Chen X-H, Zhang C, Zhang X, Gao L, Gao L, Kong P-Y, et al.. Cost and outcome in stem cell collections in HLA haploidentical mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized blood and bone marrow for patients with hematologic malignancies. Transfus Apher Sci. 2010;43:23–8.
   PubMed Web of Science ®Google Scholar
• Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, et al.. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2003;31:–205–10.
   PubMedGoogle Scholar
• Svahn B-M, Ramberger M, Alvin O, Karlsson H, Ringden O. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2011 [29 Aug; Epub ahead of print].
   Google Scholar
• Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, et al.. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007;40:209–17.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M, et al.. Do mini transplants have mini costs? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;36:649–54.
   PubMed Web of Science ®Google Scholar
• Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005;25:325–34.
   PubMed Web of Science ®Google Scholar
• Krecji M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z, et al.. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant. 2006;38:483–91.
   PubMed Web of Science ®Google Scholar
• De Lissovoy G, Hurd D, Carter S, Beatty B, Ewell M, Henslee-Downey J, et al.. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T cell depletion vs. unmanipulated grafts for the prevention of graft-versus-host disease. Bone Marrow Transplant. 2005;36:539–46.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A. Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol. 2002;117:451–68.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol. 2002;76 Suppl 1:376–9.
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D. The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol. 2002;27 Suppl 1:380–82.
   Google Scholar
• Ngamkiatphaisan S, Sriratanaban J, Kamoiratanakul P, Intraqumtomchai T, Noppakun N, Jonqudomsuk P. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2007;90:2565–73.
   PubMedGoogle Scholar
• El-Zimaity MM, Hassan EA, Abd El-Wahab SE, Abd El-Ghaffar AA, Mahmoud NA, Elafifi AM, et al.. Stem cell transplantation in hematological disorders. A developing country experience — impact of cost considerations. Saudi Med J. 2008;29:1484–9.
   PubMed Web of Science ®Google Scholar
• Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic haematopoietic transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant. 2001;28:1111–6.
   PubMed Web of Science ®Google Scholar
• Orsi C, Bartolozzi B, Messori A, Bosi A. Event-free survival and cost-effectiveness in adult acute lymphoblastic leukemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant. 2007;40:643–9.
   PubMed Web of Science ®Google Scholar
• Clarke SA, Skinner R, Guest J, Darbyshire P, Cooper J, Vora A, et al.. Clinical outcomes and health-related quality of life (HRQOL) following haemopoietic stem cell transplantation (HSCT) for paediatric leukaemia. Child Care Health Dev. 2011;37:571–80.
   PubMed Web of Science ®Google Scholar
• Watson M, Buck G, Wheatley K, Homewood JR, Goldstone AH, Rees JK, et al.. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. Eur J Cancer. 2004;40:971–6.
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332–42.
   PubMed Web of Science ®Google Scholar
• Vigdor ER. Coverage does matter: the value of health foregone by the uninsured. In: Hidden costs, value lost: uninsurance in America. Washington (DC): National Academy Press; 2003. p. 129–69.
   Google Scholar